VELO3D announces Assure™ Quality Assurance and Control System for 3D metal printing and Stratasys Direct Manufacturing as First Customer of Assure
5.11.2019 18:00:00 EET | Business Wire | Press release
VELO3D, an innovator in metal Additive Manufacturing (AM) has announced the release and availability of the VELO3D Assure™ Quality Assurance and Control System for its Sapphire® 3D metal printers. Stratasys Direct Manufacturing, a subsidiary of Stratasys, Ltd. (NASDAQ: SSYS) and one of the largest providers of additive (3D printing) and conventional manufacturing services in North America, is the first customer to implement Assure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005695/en/
VELO3D’s Assure™ quality control dashboard enables engineers to track the quality and progress of Sapphire® machines in real-time. (Graphic: Business Wire)
Assure provides substantiation of part quality needed for volume production. It detects process anomalies, flags them, and highlights the corrective actions required so errors are not repeated. Through real-time, multi-sensor, physics-based detection algorithms, Assure delivers unprecedented traceability of part quality and flags process anomalies as soon as they occur. This decreases variation and provides comprehensive documentation to fast-track printed-part validation.
“Assure is a revolutionary quality-control system, an inherent part of the VELO3D end-to-end manufacturing solution for serial production,” says Benny Buller, founder and CEO of VELO3D. “Assure is part of our vision to provide an integrated solution to produce parts by additive manufacturing with successful outcomes.”
Stratasys Direct began working with VELO3D on Assure testing soon after they acquired a Sapphire printer earlier in the year. Stratasys Direct implemented Assure to identify variations and anomalies in the production of the parts on several builds. Throughout the study, Stratasys Direct accessed Assure’s dashboard and sophisticated algorithms to monitor the integrity of the builds, validate the bulk material density, observe ongoing process metrics, and verify the calibration of the system across multiple production runs. These trials and results confirmed the capabilities of the software, and were documented in a whitepaper that both VELO3D and Stratasys Direct co-authored which can be downloaded at https://info.stratasysdirect.com/rs/626-SBR-192/images/VELO3D_ASSURE_White_Paper_201911.pdf?utm_source=pr&utm_medium=release&utm_campaign=WEBREC-2019-WP-VELO3D-ASSURE
“Stratasys Direct has built a culture of continuous improvement that means we are continually setting new standards for our industry on quality,” said Kent Firestone, CEO of Stratasys Direct Manufacturing. “We integrated Assure into our quality control workflow because it produces highly actionable insights. The user interface features intuitive graphs and charts that enable us to see and interpret the vast amount of data collected during builds. This information helps our engineers verify the quality of the build each step of the way, and enables them to make quick decisions in the event of an issue. Assure helps us reduce production variation, improve yields, and circumvent anomalies to ensure consistent additive manufacturing.”
To learn more about Assure:
-
Stratasys Direct will host a webinar on November 14th at 10am PST; please visit this link to register:
https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=&eventid=2126421&sessionid=1&key=3925B221E06F51D08CE47106E3AD4F54®Tag=&sourcepage=register - VELO3D and Stratasys Direct will host a joint press conference at the VELO3D booth (Hall 11, E79) at formnext in Frankfurt, Germany on November 19 at 10 a.m.
About VELO3D
VELO3D empowers companies to manufacture anything. By bringing together innovations in software, hardware, and process control, VELO3D created the industry’s first SupportFree solution for 3D metal printing, enabling unlimited design innovation by reducing the need for support structures in metal additive manufacturing. The company’s Sapphire® system is built with a semiconductor mindset on quality assurance, ensuring repeatability and dependability throughout serial manufacturing. Headquartered in Silicon Valley, VELO3D helps companies deliver immediate business impact by making the impossible, possible. To learn more, please visit www.velo3D.com.
About Stratasys Direct
Stratasys Direct Manufacturing Inc. is the leading provider of 3D printing and advanced manufacturing services utilizing a broad range of additive and conventional technologies. We leverage nearly 30 years of 3D printing, design and engineering experience to ensure customers’ project success in each stage of product development, from prototypes to production runs. Serving companies of all sizes, from start-ups to established global brands, we develop methods, materials and processes that optimize and enhance additive and conventional manufacturing’s capabilities. Online at: www.stratasysdirect.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005695/en/
Contact information
VELO3D
Joyce Yeung
joyce.yeung@velo3D.com
972.914.8732
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
